EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genetic risk for treatment resistant schizophrenia and corresponding variation in dopamine synthesis capacity and D2/3 receptor availability in healthy individuals

Daniel Paul Eisenberg iD, Rachael Keir Blackman, Maria G Tietcheu, Philip D Kohn, Jasmin S Bettina, Bhaskar Kolachana, Michael D Gregory, Karen F Berman iD

Molecular Psychiatry · 2025-06 · 30 (6) · 2645-2652

DOI: 10.1038/s41380-024-02873-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Psychiatry, online erschienen am 27.12.2024. Verfasst von Daniel Paul Eisenberg und 7 weiteren Autor:innen. Beteiligte Einrichtung: From the Clinical & Translational Neuroscience Branch, Intramural Research Program, National Institute of Mental Health, NIH, DHHS, Bethesda, MD, 208…. Hauptthemen laut MEDLINE: Receptors, Dopamine D2, Receptors, Dopamine D3, Dopamine, Schizophrenia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S. Department of Health & Human Services | NIH | National Institute of Mental Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dysfunction of dopamine systems has long been considered a hallmark of schizophrenia, and nearly all current first-line medication treatments block dopamine D 2 receptors. However, approximately a quarter of patients will not adequately respond to these agents and are considered treatment-resistant. Whereas abnormally high striatal presynaptic dopamine synthesis capacity has been observed in people with schizophrenia, studies of treatment-resistant patients have not shown this pattern and have even found the opposite – i.e., reductions in striatal presynaptic dopamine synthesis capacity. Whether such reductions in fact represent clinical epiphenomena such as medication or other treatment effects or whether they rather represent neurobiological differences related to etiology has been unclear. To understand the dopaminergic implications of genetic liability for treatment-resistant schizophrenia without the confound of clinical epiphenomena, we studied a cohort of healthy individuals without neuropsychiatric illness using [ 18 F]-FDOPA positron emission tomography (PET) and found that striatal presynaptic dopamine synthesis capacity showed an expected direct association with cumulative genetic risk burden for general schizophrenia but an inverse association with specific polygenic risk for treatment-resistant schizophrenia. Subsequent evaluation of D 2/3 dopamine receptor availability in an overlapping cohort using [ 18 F]-fallypride PET did not identify any effects of genetic risk in the striatum but found an association with treatment-resistant schizophrenia polygenic risk in the thalamus. Overall, these results align with prior PET studies in patients and implicate, at least with respect to the dopamine system, fundamentally distinct molecular mechanisms in the unique genetic liability for treatment-resistant schizophrenia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Dopamine D2Receptors, Dopamine D3DopamineSchizophreniaSchizophrenia, Treatment-ResistantHumansMaleFemaleAdultPositron-Emission TomographyGenetic Predisposition to DiseaseCorpus StriatumMiddle AgedDihydroxyphenylalanineCohort StudiesHealthy VolunteersPyrrolidines

Substanzen

Receptors, Dopamine D2Receptors, Dopamine D3DopamineDRD2 protein, humanDRD3 protein, humanDihydroxyphenylalaninePyrrolidines

Autor:innen und Institutionen

  • From the Clinical & Translational Neuroscience Branch, Intramural Research Program, National Institute of Mental Health, NIH, DHHS, Bethesda, MD, 20892, USA. eisenbergd@mail.nih.gov.
  • From the Clinical & Translational Neuroscience Branch, Intramural Research Program, National Institute of Mental Health, NIH, DHHS, Bethesda, MD, 20892, USA.
  • Human Brain Collection Core, Intramural Research Program, National Institute of Mental Health, NIH, DHHS, Bethesda, MD, 20892, USA.
  • From the Clinical & Translational Neuroscience Branch, Intramural Research Program, National Institute of Mental Health, NIH, DHHS, Bethesda, MD, 20892, USA. karen.berman@nih.gov.

ORCID-Profile: Daniel Paul Eisenberg, Karen F Berman

Förderung

  • U.S. Department of Health & Human Services | NIH | National Institute of Mental Health

Zitieren

APA

Eisenberg, D. P., Blackman, R. K., Tietcheu, M. G., Kohn, P. D., Bettina, J. S., Kolachana, B., Gregory, M. D., & Berman, K. F. (2025). Genetic risk for treatment resistant schizophrenia and corresponding variation in dopamine synthesis capacity and D2/3 receptor availability in healthy individuals. Molecular Psychiatry, 30(6), 2645-2652. https://doi.org/10.1038/s41380-024-02873-2

Vancouver

Eisenberg DP, Blackman RK, Tietcheu MG, Kohn PD, Bettina JS, Kolachana B, et al. Genetic risk for treatment resistant schizophrenia and corresponding variation in dopamine synthesis capacity and D2/3 receptor availability in healthy individuals. Molecular Psychiatry. 2025;30(6):2645-2652. doi:10.1038/s41380-024-02873-2

BibTeX
@article{Eisenberg2025,
  author = {Eisenberg, Daniel Paul and Blackman, Rachael Keir and Tietcheu, Maria G and Kohn, Philip D and Bettina, Jasmin S and Kolachana, Bhaskar and Gregory, Michael D and Berman, Karen F},
  title = {Genetic risk for treatment resistant schizophrenia and corresponding variation in dopamine synthesis capacity and D2/3 receptor availability in healthy individuals},
  journal = {Molecular Psychiatry},
  year = {2025},
  volume = {30},
  number = {6},
  pages = {2645--2652},
  doi = {10.1038/s41380-024-02873-2}
}
Kostenlos starten →